Investigational drug · Phase 2
YA-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Multiple System Atrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "YA-101"
First trial start
2025
Mar 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YA-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple System Atrophy
Largest trials
Live from ClinicalTrials.gov: studies naming "YA-101" as an intervention, largest first.
- A Phase 2 Study of YA-101 in Patients With Multiple System AtrophyActive, not recruiting
Dasher Neuroscience Inc.Industry
NCT06848231 · 75 participants (planned) · Start Mar 3, 2025 · Primary completion Jun 30, 2027
Drug: YA-101; Placebo · For: Multiple System Atrophy
Sites: Los Angeles, California; Boston, Massachusetts; Rochester, Minnesota · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Multiple System Atrophy
- AmlenetugLu AF82422Phase 32 trials
H. Lundbeck A/S · Multiple System Atrophy
- PBT434ATH434Phase 23 trials
Alterity Therapeutics · Multiple System Atrophy
- Foralumab NasalPhase 22 trials
Tiziana Life Sciences LTD · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
- TEV-56286EmrusolminPhase 22 trials
Teva · Multiple System Atrophy
- exidavnemabPhase 21 trial
BioArctic AB · Parkinson Disease, Multiple System Atrophy
- TAK-341MEDI1341Phase 21 trial
Takeda · Multiple System Atrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.